Maidstone-based medical manufacturer Bedfont Scientific has secured registration for its asthma breath analysis device in India, opening up a new market for the company.
The company is partnering with healthcare equipment distributor Rbeck Healthtech Private to offer its NObreath device for fractional exhaled nitric oxide (FeNO) testing across the country. FeNO testing is a key tool in assessing type 2 airway inflammation, which is commonly associated with asthma.
India is home to approximately 13.1 per cent of the world’s asthma sufferers, with many individuals undiagnosed or untreated, according to the Global Asthma Report 2022.
Jason Smith, chief executive of Bedfont, said: “Partnering with Rbeck Healthtech and the successful registration for the NObreath in India is a meaningful milestone in our mission to make precision asthma care accessible worldwide. India faces a significant burden of asthma, and we believe that FeNO testing can empower clinicians with clearer insights into airway inflammation, leading to more personalised and effective treatment decisions.”
